Pharma Tech Solutions, Inc. v. LifeScan, Inc., No. 19-1163 (Fed. Cir. Nov. 22, 2019)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

This is an appeal from the district court’s summary judgment of noninfringement under the doctrine of equiv- alents. Because prosecution history estoppel bars the claims for infringement under the doctrine of equivalents, we affirm. BACKGROUND I Pharma Tech Solutions, Inc. sued LifeScan, Inc. for in- fringement of its U.S. Patent Nos. 6,153,069 and 6,413,411, which concern blood glucose monitoring systems for home use by individuals with diabetes.